CD274 and non-small cell lung carcinoma: In routine clinical care, PD-L1 expression is crucial for selecting therapy in non-oncogene-driven NSCLC, as pembrolizumab, cemiplimab, or atezolizumab monotherapy is preferred first-line for high expressors (TPS ≥ 50%), whereas combination chemo-immunotherapy can be used regardless of PD-L1 status.